Dr Peter Roselt
Honorary (Senior Fellow)
The Sir Peter MacCallum Department of Oncology
134 Scholarly works
2 Projects
HIGHLIGHTS
2026
Journal article
Correction: Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting
DOI: 10.1039/d6ra90008a2026
Journal article
Evaluating the therapeutic efficacy of gastramide theranostics targeting cholecystokinin-2 receptors in a preclinical setting
DOI: 10.1039/d5ra08789a2026
Journal article
A scalable protocol for the radiosynthesis of clinical grade lutetium-177-labeled theranostic agents
DOI: 10.1038/s41596-025-01176-22026
Journal article
Carbonic Anhydrase-IX Is a Specific and Sensitive Theragnostic Target for Imaging and Radioimmunotherapy in Metastatic Colorectal Cancer
DOI: 10.1016/j.gastha.2025.1008712025
Journal article
Multifactorial analysis of radiochemical purity in high-activity 177Lu-labeled theranostics: impact of precursor source, 177Lu form, and production parameters
DOI: 10.1186/s41181-025-00372-52025
Conference Proceedings
Radiolabelled peptides targeting CXCR4 for cancer imaging and treatment
DOI: 10.1016/j.nucmedbio.2025.1094192025
Conference Proceedings
Dual Function, Singular Impact: Successes of a Novel Class of Theranostic Gastramide (GA) Peptides Targeting Cholecystokinin-2 Receptor
DOI: 10.1016/j.nucmedbio.2025.109530
RECENT SCHOLARLY WORKS
2025
Journal article
Automated radiosynthesis of [89Zr]ZrCl4 & [89Zr]Zr-DFOSq-Agents
DOI: 10.1016/j.nucmedbio.2025.1094432025
Journal article
A fully automated radiolabelling of [68Ga]Ga-DOTA-exendin-4 using iPhase MultiSyn synthesis module
DOI: 10.1016/j.nucmedbio.2025.1094312025
Journal article
A Scalable and Robust Protocol for the Production of Clinical Grade Lutetium-177 Labelled Therapeutics
DOI: 10.1016/j.nucmedbio.2025.109473
RECENT PROJECTS
2016
Research Grant
Molecular Imaging of Cancers With Copper and Zirconium Radiopharmaceuticals
2016
Research Grant
Molecular Imaging of Cancers With Copper and Zirconium Radiopharmaceuticals